Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Camille Gély"'
Autor:
Ofelia Feuillâtre, Camille Gély, Steve Huvelle, Christine B. Baltus, Ludovic Juen, Nicolas Joubert, Audrey Desgranges, Marie-Claude Viaud-Massuard, Camille Martin
Publikováno v:
ACS Omega, Vol 5, Iss 3, Pp 1557-1565 (2020)
Externí odkaz:
https://doaj.org/article/ee9481fb6507457dbd19485a634fd2f0
Autor:
Ludovic Juen, Christine B. Baltus, Camille Gély, Thibault Kervarrec, Ofelia Feuillâtre, Audrey Desgranges, Marie-Claude Viaud-Massuard, Camille Martin
Publikováno v:
Bioconjugate Chemistry. 33:418-426
With three clinically approved antibody-drug conjugates targeting HER2, this target is clearly identified to be of interest in oncology. Moreover, the advent of new bioconjugation technologies producing site-specific homogenous conjugates led to the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd8f2817c573aa1d1aa1fa4d9f39cfe0
https://doi.org/10.1021/acs.bioconjchem.2c00015
https://doi.org/10.1021/acs.bioconjchem.2c00015
Autor:
Audrey Desgranges, Camille Martin, Camille Gély, Marie-Claude Viaud-Massuard, Ludovic Juen, Ofelia Feuillâtre, Christine B. Baltus
Publikováno v:
Bioconjugate Chemistry. 32:595-606
To overcome stability and heterogeneity issues of antibody-drug conjugates (ADCs) produced with existing bioconjugation technologies incorporating a maleimide motif, we developed McSAF Inside, a new technology based on a trifunctionalized di(bromomet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c31313d0989be50aca9224db74205ce
https://doi.org/10.1021/acs.bioconjchem.1c00058
https://doi.org/10.1021/acs.bioconjchem.1c00058
Autor:
Ludovic Juen, Camille Gély, Audrey Desgranges, Ofelia Feuillâtre, Nicolas Joubert, Camille Martin, Christine B. Baltus, Marie-Claude Viaud-Massuard, Steve Huvelle
Publikováno v:
ACS Omega
ACS Omega, Vol 5, Iss 3, Pp 1557-1565 (2020)
ACS Omega, Vol 5, Iss 3, Pp 1557-1565 (2020)
Antibody–drug conjugates (ADCs) are the spearhead of targeted therapies. According to the technology used, the conjugation of a cytotoxic drug to an antibody can produce suboptimal heterogeneous species, impacting the overall efficacy. Herein, we d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8eca9a84065672450d88c66b3dac2ce2
https://doi.org/10.1021/acsomega.9b03510
https://doi.org/10.1021/acsomega.9b03510
Autor:
Marie-Claude Viaud-Massuard, Ludovic Juen, Ambrine Sahal, Jean-François Mirjolet, Camille Martin, Ofelia Feuillâtre, Pascal Grondin, Audrey Desgranges, Audrey Bertaux, Camille Gély, Guillaume Serin, Samira Benhamouche-Trouillet, Christine B. Baltus
Publikováno v:
Cancer Research. 80:4115-4115
Introduction: The Antibody-Drug Conjugates (ADCs)-based therapy has revealed a field of perspectives by increasing the specificity and the efficacy of the anti-tumoral drug treatment. McSAF is a company focused in bio-organic and bioconjugates chemis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d666a608c4786b701813ddcb614880e1
https://doi.org/10.1158/1538-7445.am2020-4115
https://doi.org/10.1158/1538-7445.am2020-4115